The KRT10 antibody targets keratin 10 (KRT10), a member of the type I keratin family of intermediate filament proteins. KRT10 pairs with keratin 1 (KRT1) to form the structural framework of epidermal keratinocytes, primarily in the suprabasal layers of stratified epithelia, such as the skin's spinous and granular layers. This protein is critical for maintaining epidermal integrity, mechanical resilience, and barrier function. Mutations in the KRT10 gene are linked to autosomal dominant disorders like epidermolytic ichthyosis (EI), characterized by skin fragility, blistering, and hyperkeratosis. KRT10 antibodies are widely used in research and diagnostics to study keratinocyte differentiation, skin pathology, and genetic skin diseases. In immunohistochemistry (IHC) and immunofluorescence (IF), these antibodies help visualize KRT10 expression patterns, aiding in the classification of epidermal disorders. They also serve as markers in cancer research, as altered KRT10 expression has been observed in squamous cell carcinomas and other epithelial malignancies. Commercial KRT10 antibodies are typically validated for specificity across human and model organism tissues, supporting applications in both basic science and clinical contexts.